Abivertinib synergistically strengthens the anti‐leukemia activity of venetoclax in acute myeloid leukemia in a BTK‐dependent manner

B‐cell lymphoma 2 (BCL‐2), a crucial member of the anti‐apoptotic BCL‐2 family, is frequently dysregulated in cancer and plays an important role in acute myeloid leukemia (AML). Venetoclax is a highly selective BCL‐2 inhibitor that has been approved by the FDA for treating elderly AML patients. Howe...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Shujuan Huang, Chenying Li, Xiang Zhang, Jiajia Pan, Fenglin Li, Yunfei Lv, Jingwen Huang, Qing Ling, Wenle Ye, Shihui Mao, Xin Huang, Jie Jin
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Wiley 2020-10-01
Schriftenreihe:	Molecular Oncology
Schlagworte:	abivertinib AML BTK‐dependent venetoclax
Online-Zugang:	https://doi.org/10.1002/1878-0261.12742
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!